blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2124920

EP2124920 - ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATNG CHRONIC PAIN [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  04.11.2016
Database last updated on 29.10.2024
Most recent event   Tooltip04.11.2016Application deemed to be withdrawnpublished on 07.12.2016  [2016/49]
Applicant(s)For all designated states
ALLERGAN, INC.
2525 Dupont Drive
Irvine, CA 92612 / US
[N/P]
Former [2009/49]For all designated states
ALLERGAN, INC.
2525 Dupont Drive
Irvine CA 92612 / US
Former [2008/36]For all designated states
ALLERGAN, INC.
2525 Dupont Drive
Irvine, CA 92612 / US
Inventor(s)01 / GIL, Daniel W.
2541 Point Del Mar
Corona Del Mar, CA 92625 / US
02 / DONELLO, John E.
34041 Pequito Drive
Dana Point, CA 92629 / US
 [2009/49]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[N/P]
Former [2009/49]HOFFMANN EITLE
Patent- und Rechtsanwälte Arabellastrasse 4
81925 München / DE
Application number, filing date07855143.913.12.2007
[2009/49]
WO2007US87455
Priority number, dateUS20060871716P22.12.2006         Original published format: US 871716 P
[2009/49]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008079720
Date:03.07.2008
Language:EN
[2008/27]
Type: A1 Application with search report 
No.:EP2124920
Date:02.12.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 03.07.2008 takes the place of the publication of the European patent application.
[2009/49]
Search report(s)International search report - published on:EP03.07.2008
ClassificationIPC:A61K31/195, A61K31/197, A61K31/4164, A61K31/4174, A61K31/4178, A61K45/00, A61K31/4709, A61P29/00, A61P29/02
[2009/49]
CPC:
A61K45/06 (EP,US); A61K31/195 (EP,US); A61K31/197 (EP,US);
A61K31/4164 (EP,US); A61K31/4174 (EP,US); A61K31/4709 (EP,US);
A61P25/00 (EP); A61P25/04 (EP); A61P29/00 (EP);
A61P29/02 (EP) (-)
C-Set:
A61K31/195, A61K2300/00 (EP,US);
A61K31/197, A61K2300/00 (US,EP);
A61K31/4164, A61K2300/00 (US,EP);
A61K31/4174, A61K2300/00 (US,EP);
A61K31/4709, A61K2300/00 (EP,US)
(-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/49]
TitleGerman:ALPHA-2B-REZEPTOR-AGONIST UND ANTIKONVULSIVE ZUSAMMENSETZUNG ZUR BEHANDLUNG CHRONISCHER SCHMERZEN[2009/49]
English:ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATNG CHRONIC PAIN[2009/49]
French:COMPOSITIONS D'AGONISTE DU RÉCEPTEUR ALPHA-2B ET D'ANTI-CONVULSIVANT POUR LE TRAITEMENT DE LA DOULEUR CHRONIQUE[2009/49]
Entry into regional phase21.07.2009National basic fee paid 
21.07.2009Designation fee(s) paid 
21.07.2009Examination fee paid 
Examination procedure21.07.2009Amendment by applicant (claims and/or description)
21.07.2009Examination requested  [2009/49]
20.03.2012Despatch of a communication from the examining division (Time limit: M04)
25.07.2012Reply to a communication from the examining division
22.01.2014Despatch of a communication from the examining division (Time limit: M04)
19.05.2014Reply to a communication from the examining division
01.07.2016Application deemed to be withdrawn, date of legal effect  [2016/49]
01.08.2016Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2016/49]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  20.03.2012
Fees paidRenewal fee
28.12.2009Renewal fee patent year 03
27.12.2010Renewal fee patent year 04
27.12.2011Renewal fee patent year 05
26.12.2012Renewal fee patent year 06
27.12.2013Renewal fee patent year 07
29.12.2014Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.12.201509   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO03099289  (ALLERGAN INC [US], et al) [X] 1-30 * page 6, line 25 - page 7, line 23 * * page 11, line 14 - page 12, line 34 * * page 21; table 1; compounds 3,11 * * page 30, line 23 - page 31, line 11 * * page 36, line 7 - page 37, line 6 * * page 39, line 20 - page 41, line 12 * * page 44, lines 3-35 * * page 50, lines 12-25 * * page 74, line 4 - page 75, line 10 * * page 80, lines 1-15 * * page 86, line 9 - page 91, line 5 *;
 [A]WO02076950  (ALLERGAN INC [US]) [A] 1-30 * page 2, line 11 - page 4, line 6 * * page 6, lines 16-28 * * page 41; example I * * page 90; examples B-3b,J-2 * * page 91; examples J-3 * * page 92; example I * * page 108; example 1H * * tables 2,3; compounds B-3B, J-2, J-3 * * page 118 - page 120; example CC *;
 [A]WO2006036497  (ALLERGAN INC [US], et al) [A] 1-30 * paragraphs [0003] , [0024] , [0199] - [0207] - [0221] - [0235] * * page 14; table 1; compound 7 *;
 [A]US2005059721  (CHOW KEN [US], et al) [A] 1-30 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.